Implementing a peer-supported, integrated strategy for substance use disorder care in an outpatient infectious disease clinic is associated with improved patient outcomes
Oluwaseun Falade‐Nwulia(Johns Hopkins University), Mark Sulkowski(Johns Hopkins University), Tracy Agee(Johns Hopkins University), Gregory M. Lucas(Johns Hopkins University), Ju Nyeong Park(John Brown University), J. M. Hsu(Johns Hopkins University), Catherine R. Lesko(Johns Hopkins University), Nishant R. Shah(Brigham and Women's Hospital), Jeanne Keruly(Johns Hopkins University), Sheree Schwartz(Johns Hopkins University), Sharon M. Kelly(University of Glasgow), Nicholas Schweizer(Johns Hopkins University), Joyce Jones(Johns Hopkins University)
Cited by 11
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694